FDA Extends Deramiocel PDUFA Date to November 22, 2026 After Major Amendment
CAPR has more than doubled off its 52-week low of $2.96.
Summary
FDA extended the Deramiocel PDUFA date by three months to November 22, 2026, after classifying Capricor's BLA amendment as major. The amendment includes 24-month HOPE-3 data supporting a refined upper limb function indication.
Key Events · Product Development and Regulatory · CAPR
-
PDUFA Date Extended to November 22, 2026
FDA extended the Deramiocel BLA target action date from August 22, 2026 to November 22, 2026, a three-month delay.
-
Major Amendment Classification
FDA classified Capricor's submission as a major amendment, which triggered the extended review period.
-
Refined Indication Focused on Upper Limb Function
Capricor requested FDA review of 24-month HOPE-3 open-label extension data and additional analyses supporting a refined proposed indication focused on upper limb function, the primary endpoint of HOPE-3.
-
Negative Advisory Committee Vote Precedes Extension
The extension follows the July 29, 2026 FDA advisory committee's 9-3 vote against deramiocel's effectiveness data for DMD-related heart disease.
Analysis · CAPR · Life Sciences
The FDA has pushed the Deramiocel BLA decision from August 22 to November 22, 2026, classifying Capricor's submission as a major amendment. This follows the July 29 advisory committee's 9-3 vote against the drug's effectiveness data. The extension gives Capricor three more months to convince the FDA that its 24-month HOPE-3 open-label data supports a refined indication focused on upper limb function. The delay is a double-edged sword: it keeps the approval path alive after a negative adcomm, but it also means no near-term revenue from Deramiocel and extends the company's cash burn. With $237.9M in cash as of Q2 and a $40.7M quarterly loss, the runway remains adequate but the regulatory uncertainty is now prolonged.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAPR was trading at $6.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $365.7M. The 52-week trading range was $2.96 to $40.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.